Finding the right balance between precision medicine and personalized care

CMAJ

Volumn 189, Issue 33, 2017, Pages E1065-E1068

  McAlister, Finlay A ^a,b   Laupacis, Andreas ^c   Armstrong, Paul W ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; COST CONTROL; COST UTILITY ANALYSIS; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; GENE SEQUENCE; GENETIC RISK; GENOTYPE; HEALTH CARE; HUMAN; MOLECULAR DIAGNOSIS; NOTE; PERSONALIZED CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); PATIENT CARE; PROCEDURES;

EVIDENCE-BASED MEDICINE; HUMANS; PATIENT-CENTERED CARE; PRECISION MEDICINE;

EID: 85027986145     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170107     Document Type: Article

References (33)

1. National Research Council (US) Committee on a Framework for Development of a New Taxonomy of Disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington: National Academies Press; 2011. ISBN 978-0-309-22222-8.
2. Topol EJ. Individualized medicine from pre-womb to tomb. Cell 2014; 157:241-53.
3. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526:343-50.
4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793-5.
5. McAlister FA, Straus SE, Haynes RB, et al: Evidence-based Medicine Working Group. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000; 283:2829-36.
6. Ziegelstein RC. Personomics. JAMA Intern Med 2015; 175:888-9.
7. Kroenke K. A practical and evidence-based approach to common symptoms. A narrative review. Ann Intern Med 2014; 161:579-86.
8. Armstrong PW, McAlister FA. Searching for adherence: Can we fulfill the promise of evidence-based medicines? J Am Coll Cardiol 2016; 68:802-4.
9. Paley L, Zornitzki T, Cohen J, et al. Utility of clinical examination in the diagnosis of emergency department patients admitted to the department of medicine of an academic hospital. Arch Intern Med 2011; 171:1394-96.
10. Crombie DL. Diagnostic process. J Coll Gen Pract 1963; 6:579-89.
11. Sandler G. The importance of the history in the medical clinic and the cost of unnecessary tests. Am Heart J 1980; 100:928-31.
12. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. dificile infection identified on whole-genome sequencing. N Engl J Med 2013; 369:1195-205.
13. Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364:730-9.
14. Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 2009; 7:778-831.
15. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-312.
16. Prasad V. The precision-oncology illusion. Nature 2016; 537:S63.
17. Abbasi J. Getting pharmacogenomics into the clinic. JAMA 2016; 316:1533-5.
18. Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA 2015; 314:999-1000.
19. Phillips KA, Deverka PA, Sox HC, et al. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative efectiveness research. Genet Med 2017; Apr. 1 [Epub ahead of print]. doi: 10.1038/gim.2017.21.
20. Stergiopoulos K, Brown DL. Genotype-guided vs. clinical dosing of warfarin and its analogues. Meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174:1330-8.
21. Phillips KA, Sakowski JA, Trosman J, et al. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 2014; 16:251-7.
22. Khoury MJ, Galea S. Will precision medicine improve population health? JAMA 2016; 316:1357-8.
23. Ford ES, Bergmann MM, Boeing H, et al. Healthy lifestyle behaviors and all-cause mortality among adults in the United States. Prev Med 2012; 55:23-7.
24. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016; 18:421-30.
25. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014; 311:1035-45.
26. Feero WG. Clinical application of whole-genome sequencing proceed with care. JAMA 2014; 311:1017-9.
27. Hollands GJ, French DP, Grifin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 2016; Mar. 15; 352:i1102.
28. Bloss CS, Schork NJ, Topol EJ. Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. J Med Genet 2014; 51:83-9.
29. Dzau VJ, Ginsburg GS, Van Nuys K, et al. Aligning incentives to fulfill the promise of personalised medicine. Lancet 2015; 385:2118-9.
30. Joyner MJ, Paneth N, Ioannidis JPA. What happens when underperforming big ideas in research become entrenched? JAMA 2016; 316:1355-6.
31. Kontopantelis E, Springate DA, Ashworth M, et al. Investigating the relationship between quality of primary care and premature mortality in England: a spatial whole-population study. BMJ 2015; 350:h904.
32. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793-5.
33. Caulfield T, Evans J, McGuire A, et al. Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol 2013; 11:e1001699.